Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Corporate Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases May 20, 2022 CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) May 11, 2022 FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 May 5, 2022 Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease All press releases Latest Events May 17 2022 May 17 2022 RBC Capital Markets Healthcare Conference Webcast May 3 2022 May 3 2022 Q1 2022 Incyte Corporation Earnings Conference Call Webcast All events
